The phase III CheckMate -67T trial, evaluating the subcutaneous formulation of Opdivo (nivolumab) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) (herein referred to as “subcutaneous nivolumab”) compared to intravenous Opdivo in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy, demonstrated noninferiority for the co-primary endpoints of Cavgd28 (time-averaged Opdivo serum concentration over 28 days) and Cminss (trough serum concentration at steady state) compared to IV Opdivo.
The World Health Organization cancer agency, the International Agency for Research on Cancer, has released the latest estimates of the global burden of cancer.
Researchers have identified a next-generation BTK degrader that could help overcome treatment resistance in chronic lymphocytic leukemia and related blood cancers.
UCLA Health Jonsson Comprehensive Cancer Center researchers have identified a protein, UCHL1, in highly aggressive neuroendocrine carcinomas and neuroblastoma that could potentially be used as a molecular biomarker for diagnosing these cancers and predicting and monitoring responses to therapy.
Rice University researchers in the lab of chemist Han Xiao have identified a promising new immunological pathway to treat stubborn bone tumors, one of most prevalent forms of metastases in breast cancer patients.
A 10-year follow-up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision-making in terms of treatments and side effects for a diverse population.
A study examined the rates of active surveillance use and evaluated the factors associated with selecting this management strategy over surgery or radiation in low-risk prostate cancer, with a focus on underserved Black patients who have been underrepresented in prior studies.
The NEST-1 study, which is evaluating botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colorectal cancer, both those with Microsatellite Stable (MSS) CRC and Microsatellite Instability High CRC (MSI-High), has demonstrated positive results.
The current standard of care for identifying targetable mutations in cancer treatment is to conduct molecular profiles on tumor tissue samples, but a study published in JAMA Network Open indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.
Fred Hutchinson Cancer Center researchers, led by Jonathan Bricker, launched an AI-powered chatbot app called QuitBot to help more people successfully quit smoking cigarettes.
